Abstract
Coronavirus disease 2019 (COVID-19), a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), is growing at an exponential rate worldwide. Manifestations of this disease are heterogeneous; however, advanced cases often exhibit various acute respiratory distress syndrome-like symptoms, systemic inflammatory reactions, coagulopathy, and organ involvements. A common theme in advanced COVID-19 is unrestrained immune activation, classically referred to as a “cytokine storm”, as well as deficiencies in immune regulatory mechanisms such as T regulatory cells. While mesenchymal stem cells (MSCs) themselves are objects of cytokine regulation, they can secrete cytokines to modulate immune cells by inducing anti-inflammatory regulatory Treg cells, macrophages and neutrophils; and by reducing the activation of T and B cells, dendritic and nature killer cells. Consequently, they have therapeutic potential for treating severe cases of COVID-19. Here we discuss the unique ability of MSCs, to act as a “living anti-inflammatory”, which can “rebalance” the cytokine/immune responses to restore equilibrium. We also discuss current MSC trials and present different concepts for optimization of MSC therapy in patients with COVID-19 acute respiratory distress syndrome.
| Original language | English |
|---|---|
| Pages (from-to) | 1067-1079 |
| Number of pages | 13 |
| Journal | World Journal of Stem Cells |
| Volume | 12 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 26 2020 |
Keywords
- Acute
- COVID-19
- Cytokine storm
- Immunomodulation
- Mesenchymal stem cells
- SARS-CoV-2
- respiratory distress syndrome
Fingerprint
Dive into the research topics of 'Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver